Beacon releases a disclosure on DSE website today
For years, investors believed that Beacon Pharmaceuticals was an export-driven company, contributing to the country’s economy and increasing its profitability. But beneath the surface, the reality was quite different.
Beacon Pharmaceuticals, which makes more than 200 generic drugs and 65 oncology products, saw a 7.38 percent decline in profits during the July-March period of 2023-24, owing mainly to a rise in interest rates
Beacon Pharmaceuticals Limited posted an 8.3 per cent higher profit at Tk 93.56 crore in the financial year that ended on June 30.
